| Literature DB >> 27762623 |
H Jack Baskin, Rhoda H Cobin, Daniel S Duick, Hossein Gharib, Richard B Guttler, Michael M Kaplan, Robert L Segal, Jeffrey R Garber, Carlos R Hamilton, Yehuda Handelsman, Richard Hellman, John S Kukora, Philip Levy, Pasquale J Palumbo, Steven M Petak, Herbert I Rettinger, Helena W Rodbard, F John Service, Talla P Shankar, Sheldon S Stoffer, John B Tourtelot.
Abstract
These clinical practice guidelines summarize the recommendations of the American Association of Clinical Endocrinologists for the diagnostic evaluation of hyperthyroidism and hypothyroidism and for treatment strategies in patients with these disorders. The sensitive thyroid-stimulating hormone (TSH or thyrotropin) assay has become the single best screening test for hyperthyroidism and hypothyroidism, and in most outpatient clinical situations, the serum TSH is the most sensitive test for detecting mild thyroid hormone excess or deficiency. Therapeutic options for patients with Graves' disease include thyroidectomy (rarely used now in the United States), antithyroid drugs (frequently associated with relapses), and radioactive iodine (currently the treatment of choice). In clinical hypothyroidism, the standard treatment is levothyroxine replacement, which must be tailored to the individual patient. Awareness of subclinical thyroid disease, which often remains undiagnosed, is emphasized, as is a system of care that incorporates regular follow-up surveillance by one physician as well as education and involvement of the patient.Entities:
Keywords: AACE = American Association of Clinical Endocrinologists; RIA = radioimmunoassay; T3 = triiodothyronine; T4 = thyroxine; TRAb = thyrotropin receptor antibodies; TSH = thyroid-stimulating hormone (thyrotropin); TSI = thyroid-stimulating immunoglobulins
Year: 2002 PMID: 27762623 DOI: 10.4158/1934-2403-8.6.457
Source DB: PubMed Journal: Endocr Pract ISSN: 1530-891X Impact factor: 3.443